HAII Corp. Global

Stay connected with our recent developments

2025
2024
2023
2022

Chosun. (November 25, 2024)

Korea’s 5th Digital Therapeutic: Anzeilax Aims to Treat Generalized Anxiety Disorder

Developed by HAII Corp., led by Jinwoo Kim, Anzeilax has completed clinical trials and applied for approval from the Ministry of Food and Drug Safety, marking a new step in digital healthcare innovation.

MoneyToday. (November 4, 2024)

Suwon Science University Enhances Mental Health Support Through Digital Therapeutics Partnership

HAII Corp to Provide 'Mind Check' and 'Mind Garden' Services for University Community,

Expanding Digital Healthcare with Joint Research Initiatives

ByLineNetwork. (October 4, 2024)

HAII Expands Digital Therapeutics Innovation from South Korea to the U.S.

Pioneering AI-driven diagnostics and treatments, HAII targets global markets with solutions for dementia, stroke recovery, and anxiety, partnering with top institutions like Harvard to push forward clinical advancements.

EToday. (September 2, 2024)

HAII's 'Alzguard-T' Selected as an Innovation Product by the Public Procurement Service

HAII's cognitive function evaluation and improvement service, Alzguard-T, was chosen as an innovation product by Korea's Public Procurement Service, designed to help prevent dementia through brain tests and training for older adults.

AsiaTechDaily. (August 27, 2024)

HAII's 'Repeech' Gains US Approval for Key Clinical Trials

HAII Corporation has received US Institutional Review Board (IRB) approval from the Massachusetts General Hospital to initiate clinical trials for its digital speech rehabilitation therapeutic, “Repeech,” aimed at assisting stroke patients in

regaining speech capabilities.

KoreaTechDesk. (August 9, 2024)

HAII Secures Second Place in KHIDI-Roche Diagnostics Day's "New Impact Project"

HAII's strong performance in the competition highlights its potential for global expansion in the digital biomarker and AI healthcare sectors, positioning the company for significant international growth.

AITimes. (July 2, 2024)

HAII Highlights Role of Explainable AI in Digital Health at XAI Workshop 2024

At the ‘KCC XAI Workshop 2024,’ HAII presented its advancements in digital therapeutics, showcasing how explainable AI enhances patient trust and clinical outcomes, particularly through its speech therapy app, “Repeech,” which leverages XAI for improved transparency and personalized treatment.

HealthInNews. (June 18, 2024)

HAII Signs Comprehensive Partnership Agreement with IM Rehabilitation Hospital

HAII and IM Rehabilitation Hospital have entered into a collaboration to develop and commercialize the digital therapeutic "Repeech" for stroke-related speech and cognitive rehabilitation.

BioTimes (April 25, 2024)

HAII Secures MFDS Approval for Confirmatory Clinical Trials of Dementia Diagnostic Digital Device

HAII becomes the first in South Korea to receive MFDS approval for clinical trials of its diagnostic digital device, Alzguard, which uses digital biomarkers like voice, eye movement, and cognitive response for early detection.

ENewToday. (February 26, 2024)

HAII Receives Approval from the MFDS for Confirmatory Clinical Trials of ‘Repeech’

HAII has secured approval from South Korea’s Ministry of Food and Drug Safety (MFDS) to conduct confirmatory clinical trials for its digital speech therapy solution ‘Repeech,’ designed to aid post-stroke patients in speech rehabilitation through a mobile app.

Stay connected with our recent developments

Sign up for our

Newsletter